Article info

Download PDFPDF
APEX: a phase II randomised clinical trial evaluating the safety and preliminary efficacy of oral X-82 to treat exudative age-related macular degeneration

Authors

  1. Correspondence to Michael N Cohen, Ophthalmic Consultants of Boston, 50, Staniford Street, Suite 600, Boston, MA 02114, USA; mcohen{at}midatlanticretina.com
View Full Text

Citation

Cohen MN, O’Shaughnessy D, Fisher K, et al
APEX: a phase II randomised clinical trial evaluating the safety and preliminary efficacy of oral X-82 to treat exudative age-related macular degeneration

Publication history

  • Received April 13, 2020
  • Revised May 21, 2020
  • Accepted May 29, 2020
  • First published June 25, 2020.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.